Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who May Qualify: - Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung cancer, platinum-resistant serous ovarian cancer, cholangiocarcinoma or urothelial bladder cancer - Progressive disease following at least one line of standard of care therapy - Measurable disease as defined by RECIST v1.1 - ECOG ≤ 1 Who Should NOT Join This Trial: - Active systemic infection requiring anti-infective therapy within 28 days prior to first dose of IMP - Active cardiovascular disease - Having a second active primary malignancy, requiring systemic administration of any cancer-related therapy - Liver dysfunction - Untreated brain metastasis and/or unstable neurological dysfunction - Inflammatory bowel disease - Active and untreated hyperthyroidism - Lupus erythematosus within past 5 years Always talk to your doctor about whether this trial is right for you.